Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

P Cannon

Showing results (231-240 of 1,137) with videos related to

Pageof 114
Sort By:
American Heart Journal|November 5, 2003
Optimizing glycoprotein IIb/IIIa receptor antagonist use for the non-ST-segment elevation acute coronary syndromes: risk stratification and therapeutic interventionJames L Januzzi, Christopher P Cannon, Pierre Theroux, et al.
Clinical Microbiology and Infection : the Official Publication of the European Society of Clinical Microbiology and Infectious Diseases|February 1, 2005
Pericardial infection caused by Brevibacterium caseiJ P Cannon, S L Spandoni, S Pesh-Iman, et al.
American Heart Journal|August 1, 2006
Clinical trial design and patient demographics of the Multinational Etoricoxib and Diclofenac Arthritis Long-term (MEDAL) study program: cardiovascular outcomes with etoricoxib versus diclofenac in patients with osteoarthritis and rheumatoid arthritisChristopher P Cannon, Sean P Curtis, James A Bolognese, et al.
Journal of the American College of Cardiology|July 18, 2018
The Evolving Future of PCSK9 InhibitorsRobert S Rosenson, Robert A Hegele, Sergio Fazio, et al.
JACC. Heart Failure|December 1, 2022
Uptake of Newer Guideline-Directed Therapies in Heart Failure Patients With Diabetes or Chronic Kidney DiseaseMario Enrico Canonico, Judith Hsia, Christopher P Cannon, et al.
Journal of Interventional Cardiology|March 9, 1995
The Thrombolysis in Myocardial Infarction (TIMI) trials: the first decadeC P Cannon, E Braunwald, C H McCabe, et al.
Critical Pathways in Cardiology|December 20, 2007
Evaluation of proton pump inhibitor use in patients with acute coronary syndromes based on risk factors for gastrointestinal bleedGeoffrey C Schreiner, Loren Laine, Sabina A Murphy, et al.
Frontiers in Immunology|March 22, 2019
A Soluble Immune Effector Binds Both Fungi and Bacteria via Separate Functional DomainsAssunta Liberti, John P Cannon, Gary W Litman, et al.
Developmental and Comparative Immunology|July 2, 2014
Immune-directed support of rich microbial communities in the gut has ancient rootsLarry J Dishaw, John P Cannon, Gary W Litman, et al.
Alimentary Pharmacology & Therapeutics|October 20, 2010
Risk factors for NSAID-associated upper GI clinical events in a long-term prospective study of 34 701 arthritis patientsL Laine, S P Curtis, B Cryer, et al.
Pageof 114

Showing results (231-240 of 1,137) with videos related to

Sort By:
Pageof 114
American Heart Journal|November 5, 2003
Optimizing glycoprotein IIb/IIIa receptor antagonist use for the non-ST-segment elevation acute coronary syndromes: risk stratification and therapeutic interventionJames L Januzzi, Christopher P Cannon, Pierre Theroux, et al.
Clinical Microbiology and Infection : the Official Publication of the European Society of Clinical Microbiology and Infectious Diseases|February 1, 2005
Pericardial infection caused by Brevibacterium caseiJ P Cannon, S L Spandoni, S Pesh-Iman, et al.
American Heart Journal|August 1, 2006
Clinical trial design and patient demographics of the Multinational Etoricoxib and Diclofenac Arthritis Long-term (MEDAL) study program: cardiovascular outcomes with etoricoxib versus diclofenac in patients with osteoarthritis and rheumatoid arthritisChristopher P Cannon, Sean P Curtis, James A Bolognese, et al.
Journal of the American College of Cardiology|July 18, 2018
The Evolving Future of PCSK9 InhibitorsRobert S Rosenson, Robert A Hegele, Sergio Fazio, et al.
JACC. Heart Failure|December 1, 2022
Uptake of Newer Guideline-Directed Therapies in Heart Failure Patients With Diabetes or Chronic Kidney DiseaseMario Enrico Canonico, Judith Hsia, Christopher P Cannon, et al.
Journal of Interventional Cardiology|March 9, 1995
The Thrombolysis in Myocardial Infarction (TIMI) trials: the first decadeC P Cannon, E Braunwald, C H McCabe, et al.
Critical Pathways in Cardiology|December 20, 2007
Evaluation of proton pump inhibitor use in patients with acute coronary syndromes based on risk factors for gastrointestinal bleedGeoffrey C Schreiner, Loren Laine, Sabina A Murphy, et al.
Frontiers in Immunology|March 22, 2019
A Soluble Immune Effector Binds Both Fungi and Bacteria via Separate Functional DomainsAssunta Liberti, John P Cannon, Gary W Litman, et al.
Developmental and Comparative Immunology|July 2, 2014
Immune-directed support of rich microbial communities in the gut has ancient rootsLarry J Dishaw, John P Cannon, Gary W Litman, et al.
Alimentary Pharmacology & Therapeutics|October 20, 2010
Risk factors for NSAID-associated upper GI clinical events in a long-term prospective study of 34 701 arthritis patientsL Laine, S P Curtis, B Cryer, et al.
Pageof 114